{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:24:16Z","timestamp":1787315056113,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmig.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Minimally Invasive Gynecology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jmig.2026.07.032","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:21:40Z","timestamp":1785338500000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing MAUDE Reports for Xenform Bovine Dermal Matrix in Transvaginal Pelvic Organ Prolapse Repair: A Mixed-Methods Descriptive Analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-932X","authenticated-orcid":false,"given":"Megan","family":"Corn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-5875","authenticated-orcid":false,"given":"Eric R.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmig.2026.07.032_bib0001","article-title":"Global burden and trends of pelvic organ prolapse associated with aging women: an observational trend study from 1990 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.jmig.2026.07.032_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2008.09.013","article-title":"Extracellular matrix as a biological scaffold material: structure and function","volume":"5","author":"Badylak","year":"2009","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jmig.2026.07.032_bib0003","article-title":"Transvaginal mesh or grafts or native tissue repair for vaginal prolapse","volume":"3","author":"Yeung","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jmig.2026.07.032_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00192-019-04035-3","article-title":"Reoperation rates for pelvic organ prolapse repairs with biologic and synthetic grafts in a large population-based cohort","volume":"31","author":"Sohlberg","year":"2020","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.jmig.2026.07.032_bib0005","unstructured":"U.S. Food and Drug Administration. Urogynecologic surgical mesh implants. https:\/\/www.fda.gov\/medical-devices\/implants-and-prosthetics\/urogynecologic-surgical-mesh-implants. 2021. Accessed April 11, 2026."},{"key":"10.1016\/j.jmig.2026.07.032_bib0006","unstructured":"U.S. Food and Drug Administration. FDA\u2019s activities: urogynecologic surgical mesh. https:\/\/www.fda.gov\/medical-devices\/urogynecologic-surgical-mesh-implants\/fdas-activities-urogynecologic-surgical-mesh. 2024. Accessed April 11, 2026."},{"key":"10.1016\/j.jmig.2026.07.032_bib0007","unstructured":"Boston Scientific. Boston Scientific responds to FDA\u2019s decision to remove surgical transvaginal mesh as treatment option for POP. https:\/\/news.bostonscientific.com\/fda-decision-on-transvaginal-mesh-for-POP. 2019. Accessed April 11, 2026."},{"key":"10.1016\/j.jmig.2026.07.032_bib0008","unstructured":"U.S. Food and Drug Administration. Manufacturer and User Facility Device Experience (MAUDE). https:\/\/www.fda.gov\/medical-devices\/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities\/manufacturer-and-user-facility-device-experience-maude. 2024. Accessed April 11, 2026."},{"key":"10.1016\/j.jmig.2026.07.032_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2490-10-21","article-title":"A multicenter prospective trial evaluating fetal bovine dermal graft (Xenform\u00ae Matrix) for pelvic reconstructive surgery","volume":"10","author":"Goldstein","year":"2010","journal-title":"BMC Urol"},{"key":"10.1016\/j.jmig.2026.07.032_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.urology.2022.06.003","article-title":"Thirty-six-month prospective study of transvaginal bovine graft versus native tissue repair for pelvic organ prolapse","volume":"167","author":"Lipetskaia","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.jmig.2026.07.032_bib0011","unstructured":"U.S. Food and Drug Administration. FDA safety communication: update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse. https:\/\/www.fda.gov\/medical-devices\/safety-communications\/fda-safety-communication-update-serious-complications-associated-transvaginal-placement-surgical-mesh. 2011. Accessed May 18, 2026."},{"key":"10.1016\/j.jmig.2026.07.032_bib0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/SPV.0000000000000433","article-title":"The truth behind transvaginal mesh litigation: devices, timelines, and provider characteristics","volume":"24","author":"Souders","year":"2018","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.jmig.2026.07.032_bib0013","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4111\/icu.2018.59.2.126","article-title":"An evaluation of the MAUDE database that inspired the U.S. Food and Drug Administration\u2019s reclassification of transvaginal mesh","volume":"59","author":"Sandberg","year":"2018","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.jmig.2026.07.032_bib0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/GME.0000000000001661","article-title":"Vaginal energy-based devices: characterization of adverse events based on the last decade of MAUDE safety reports","volume":"28","author":"Wallace","year":"2021","journal-title":"Menopause"},{"key":"10.1016\/j.jmig.2026.07.032_bib0015","unstructured":"U.S. Food and Drug Administration. Problems reported with Essure. https:\/\/www.fda.gov\/medical-devices\/essure-permanent-birth-control\/problems-reported-essure. 2025. Accessed June 29, 2026."},{"key":"10.1016\/j.jmig.2026.07.032_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2023.1172927","article-title":"Safety reporting of Essure medical device: a qualitative and quantitative assessment on the FDA Manufacturer and User Facility Device Experience database in 2018","volume":"5","author":"Zou","year":"2023","journal-title":"Front Reprod Health"}],"container-title":["Journal of Minimally Invasive Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553465026004073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553465026004073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:40:07Z","timestamp":1787312407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553465026004073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":16,"alternative-id":["S1553465026004073"],"URL":"https:\/\/doi.org\/10.1016\/j.jmig.2026.07.032","relation":{},"ISSN":["1553-4650"],"issn-type":[{"value":"1553-4650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing MAUDE Reports for Xenform Bovine Dermal Matrix in Transvaginal Pelvic Organ Prolapse Repair: A Mixed-Methods Descriptive Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Minimally Invasive Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmig.2026.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of AAGL. CCBYLICENSE","name":"copyright","label":"Copyright"}]}}